JP2017531430A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531430A5
JP2017531430A5 JP2017518478A JP2017518478A JP2017531430A5 JP 2017531430 A5 JP2017531430 A5 JP 2017531430A5 JP 2017518478 A JP2017518478 A JP 2017518478A JP 2017518478 A JP2017518478 A JP 2017518478A JP 2017531430 A5 JP2017531430 A5 JP 2017531430A5
Authority
JP
Japan
Prior art keywords
car
imp
inhibitory
dimerization
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017518478A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531430A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/073197 external-priority patent/WO2016055551A1/en
Publication of JP2017531430A publication Critical patent/JP2017531430A/ja
Publication of JP2017531430A5 publication Critical patent/JP2017531430A5/ja
Pending legal-status Critical Current

Links

JP2017518478A 2014-10-07 2015-10-07 Carによって誘導される免疫細胞の活性を調節するための方法 Pending JP2017531430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201470623 2014-10-07
DKPA201470623 2014-10-07
PCT/EP2015/073197 WO2016055551A1 (en) 2014-10-07 2015-10-07 Method for modulating car-induced immune cells activity

Publications (2)

Publication Number Publication Date
JP2017531430A JP2017531430A (ja) 2017-10-26
JP2017531430A5 true JP2017531430A5 (cg-RX-API-DMAC7.html) 2018-11-08

Family

ID=51730284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017518478A Pending JP2017531430A (ja) 2014-10-07 2015-10-07 Carによって誘導される免疫細胞の活性を調節するための方法

Country Status (12)

Country Link
US (1) US10472613B2 (cg-RX-API-DMAC7.html)
EP (1) EP3204491A1 (cg-RX-API-DMAC7.html)
JP (1) JP2017531430A (cg-RX-API-DMAC7.html)
KR (1) KR20170068539A (cg-RX-API-DMAC7.html)
CN (1) CN107109368A (cg-RX-API-DMAC7.html)
AU (1) AU2015330017A1 (cg-RX-API-DMAC7.html)
BR (1) BR112017007003A2 (cg-RX-API-DMAC7.html)
CA (1) CA2963327A1 (cg-RX-API-DMAC7.html)
IL (1) IL251429A0 (cg-RX-API-DMAC7.html)
MX (1) MX2017004603A (cg-RX-API-DMAC7.html)
RU (1) RU2017115808A (cg-RX-API-DMAC7.html)
WO (1) WO2016055551A1 (cg-RX-API-DMAC7.html)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3300745T3 (pl) 2013-02-15 2020-03-31 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
EP4400516A1 (en) 2014-12-15 2024-07-17 The Regents of the University of California Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
US20170151281A1 (en) 2015-02-19 2017-06-01 Batu Biologics, Inc. Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
CN114634943A (zh) 2015-05-18 2022-06-17 T细胞受体治疗公司 使用融合蛋白对tcr重编程的组合物和方法
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
TW202444897A (zh) * 2015-06-25 2024-11-16 美商生物細胞基因治療有限公司 嵌合抗原受體(car)、組合物及其使用方法
US20210206826A1 (en) * 2015-11-19 2021-07-08 The Regents Of The University Of California Conditionally repressible immune cell receptors and methods of use thereof
SG10201913805RA (en) * 2016-01-08 2020-03-30 Univ California Conditionally active heterodimeric polypeptides and methods of use thereof
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
CN109641047A (zh) 2016-05-20 2019-04-16 哈普恩治疗公司 单结构域血清白蛋白结合蛋白质
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
EP3494138A1 (en) 2016-08-02 2019-06-12 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
ES2811500T3 (es) 2016-10-04 2021-03-12 Prec Biosciences Inc Dominios coestimuladores para su uso en células genéticamente modificadas
GB2564823B8 (en) 2016-10-07 2022-06-29 Tcr2 Therapeutics Inc Compositions and methods for TCR reprogramming using fusion proteins
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN118562882B (zh) 2016-11-22 2025-08-08 新加坡国立大学 用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
WO2018160754A2 (en) 2017-02-28 2018-09-07 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
WO2018164948A1 (en) * 2017-03-09 2018-09-13 The Scripps Research Institute Vectors with self-directed cpf1-dependent switches
CN121159691A (zh) 2017-05-12 2025-12-19 哈普恩治疗公司 间皮素结合蛋白质
CN110913908B (zh) 2017-05-12 2022-05-27 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
CN110621694A (zh) * 2017-05-15 2019-12-27 奥托路斯有限公司 包含嵌合抗原受体(car)的细胞
US12275787B2 (en) 2017-06-21 2025-04-15 Icell Gene Therapeutics Llc Chimeric antigen receptors (CARs), compositions and methods thereof
US20190038733A1 (en) 2017-08-10 2019-02-07 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
KR20200055037A (ko) 2017-09-19 2020-05-20 메사추세츠 인스티튜트 오브 테크놀로지 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도
EA202090817A1 (ru) 2017-10-13 2020-09-08 Харпун Терапьютикс, Инк. Триспецифические белки и способы их применения
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
WO2019079486A1 (en) * 2017-10-18 2019-04-25 Intrexon Corporation POLYPEPTIDE COMPOSITIONS COMPRISING SPACERS
WO2019076486A1 (en) * 2017-10-19 2019-04-25 Cellectis TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR ENHANCED IMMUNE CELL THERAPY
GB201717524D0 (en) 2017-10-25 2017-12-06 Autolus Ltd Vectors
SG11202005307RA (en) * 2017-12-14 2020-07-29 Bluebird Bio Inc Nkg2d daric receptors
JP7394058B2 (ja) * 2017-12-21 2023-12-07 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト 新規抗原結合部分の特異性試験のためのユニバーサルレポーター細胞アッセイ
CN111867619A (zh) 2018-01-03 2020-10-30 曲生物制品公司 过继性细胞治疗的先天寻靶
WO2019169290A1 (en) * 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
CA3093078A1 (en) 2018-03-06 2019-09-12 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
MX2020010808A (es) 2018-04-13 2021-03-02 Sangamo Therapeutics France Receptor de antigeno quimerico especifico para el receptor de interleucina-23.
SG11202011330PA (en) 2018-05-14 2020-12-30 Harpoon Therapeutics Inc Binding moiety for conditional activation of immunoglobulin molecules
AU2019275076B2 (en) 2018-05-23 2024-12-19 National University Of Singapore Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
KR20210023878A (ko) * 2018-06-19 2021-03-04 난징 레전드 바이오테크 씨오., 엘티디. 조작된 세포 및 이의 용도
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
AU2019346466A1 (en) 2018-09-25 2021-05-20 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
KR20210068478A (ko) 2018-09-28 2021-06-09 메사추세츠 인스티튜트 오브 테크놀로지 콜라겐-국재화된 면역조정성 분자 및 그의 방법
EP3876977A1 (en) 2018-11-06 2021-09-15 The Regents Of The University Of California Chimeric antigen receptors for phagocytosis
CN113347991B (zh) 2019-01-23 2024-07-30 美天施生物科技有限两合公司 用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
JP7633937B2 (ja) 2019-03-01 2025-02-20 アロジーン セラピューティクス,インコーポレイテッド Pd-1外部ドメインを担持するキメラサイトカイン受容体
AU2020232597B2 (en) 2019-03-01 2025-08-07 Allogene Therapeutics, Inc. Constitutively active chimeric cytokine receptors
US11013764B2 (en) 2019-04-30 2021-05-25 Myeloid Therapeutics, Inc. Engineered phagocytic receptor compositions and methods of use thereof
CN110079504A (zh) * 2019-05-06 2019-08-02 山东大学第二医院 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法
US20200384029A1 (en) * 2019-06-07 2020-12-10 The Trustees Of The University Of Pennsylvania Dual car expressing t cells individually linked to cd28 and 4-1bb
EP3990491A1 (en) 2019-06-26 2022-05-04 Massachusetts Institute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
MX2022002613A (es) 2019-09-03 2022-06-02 Myeloid Therapeutics Inc Metodos y composiciones para la integracion del genoma.
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
MX2022005443A (es) * 2019-11-05 2022-08-10 Janssen Biotech Inc Terapia con células t car dirigidas a bcma contra el mieloma múltiple.
US10980836B1 (en) 2019-12-11 2021-04-20 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods of manufacturing and use thereof
CN115066249A (zh) 2020-02-04 2022-09-16 美天施生物科技有限两合公司 表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
CA3170833A1 (en) 2020-02-21 2021-08-26 Harpoon Therapeutics, Inc. Flt3 binding proteins and methods of use
CN115175929A (zh) 2020-02-24 2022-10-11 艾洛基治疗公司 活性增强的bcma car-t细胞
US20210340524A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12433954B2 (en) 2020-05-01 2025-10-07 Massachusetts Institute Of Technology Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
US12286465B2 (en) 2020-05-28 2025-04-29 Miltenyi Biotec B.V. & Co. KG Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
CN112080527A (zh) * 2020-09-16 2020-12-15 南京市第一医院 重组表达载体、耗竭减少的嵌合抗原受体t细胞及其应用
GB2617474A (en) 2020-11-04 2023-10-11 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
WO2022096664A1 (en) 2020-11-09 2022-05-12 Miltenyi Biotec B.V. & Co. KG Methods and compositions for eliminating engineered immune cells
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス,インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2022165378A1 (en) * 2021-01-29 2022-08-04 Outpace Bio, Inc. Small molecule-regulated cell signaling expression system
GB2623191A (en) 2021-03-17 2024-04-10 Myeloid Therapeutics Inc Engineered chimeric fusion protein compositions and methods of use thereof
GB2623653A (en) 2021-05-11 2024-04-24 Myeloid Therapeutics Inc Methods and compositions for genomic integration
US20250235477A1 (en) 2021-10-06 2025-07-24 Miltenyi Biotec B.V. & Co. KG Method for targeted gene insertion into immune cells
WO2023081715A1 (en) 2021-11-03 2023-05-11 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2024078995A1 (en) 2022-10-15 2024-04-18 Miltenyi Biotec B.V. & Co. KG Transduction of gammadelta t cells with pseudotyped retroviral vectors
JP2025535365A (ja) * 2022-10-18 2025-10-24 カイト ファーマ インコーポレイテッド Il18と結合した新規cd19結合体を含むcar-t構築物およびその使用方法
CN116023507A (zh) * 2022-10-25 2023-04-28 中国医学科学院基础医学研究所 嵌合抗原受体巨噬细胞在实体肿瘤免疫治疗中的应用
WO2024227145A1 (en) * 2023-04-27 2024-10-31 Memorial Sloan-Kettering Cancer Center Enhanced fusion polypeptide for immunotherapy
KR102764613B1 (ko) * 2024-03-28 2025-02-12 한양대학교 에리카산학협력단 NaPi2b 특이적 CAR-T를 포함하는 난소암 치료용 약학 조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
PL3300745T3 (pl) * 2013-02-15 2020-03-31 The Regents Of The University Of California Chimeryczny receptor antygenowy i sposoby jego zastosowania
CN105339498A (zh) 2013-03-07 2016-02-17 贝勒医学院 癌症中靶向cd138
AU2014240083C1 (en) 2013-03-15 2019-10-24 Celgene Corporation Modified T lymphocytes
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19

Similar Documents

Publication Publication Date Title
JP2017531430A5 (cg-RX-API-DMAC7.html)
RU2017115808A (ru) Способ модуляции активности car-индуцированных иммунных клеток
TWI790213B (zh) 用於使用融合蛋白之tcr重編程的組合物及方法
Cheng et al. In vivo expansion and antitumor activity of coinfused CD28-and 4-1BB-engineered CAR-T cells in patients with B cell leukemia
CN105683214B (zh) 触发针对多种肿瘤的抗体依赖细胞毒性的嵌合受体
AU2019330347B2 (en) A method to specifically stimulate survival and expansion of genetically-modified immune cells
JP6905163B2 (ja) サイトカイン放出症候群を予測するバイオマーカー
JP7604366B2 (ja) 遺伝子操作されたt細胞を作製するための方法
JP7388798B2 (ja) Suv39h1を欠損する免疫細胞
JP2020517705A (ja) オリゴマー粒子試薬およびその使用方法
US20210189336A1 (en) Bite-activated car-t cells
JP2018529327A5 (cg-RX-API-DMAC7.html)
RU2018107802A (ru) Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин
JP2017513478A5 (cg-RX-API-DMAC7.html)
JP2019514393A (ja) 細胞に基づくネオ抗原ワクチンおよびその使用
Maryamchik et al. New directions in chimeric antigen receptor T cell [CAR‐T] therapy and related flow cytometry
Alonso-Camino et al. CARbodies: human antibodies against cell surface tumor antigens selected from repertoires displayed on T cell chimeric antigen receptors
WO2017064084A1 (en) Novel chimeric antigen receptors
KR20230007559A (ko) 태그된 키메라 이펙터 분자 및 그의 리셉터
JP2018529380A5 (cg-RX-API-DMAC7.html)
AU2017249698A1 (en) Ex vivo bite-activated T cells
Xu et al. HIV-1 and SIV predominantly use CCR5 expressed on a precursor population to establish infection in T follicular helper cells
Birley et al. A novel anti-B7-H3 chimeric antigen receptor from a single-chain antibody library for immunotherapy of solid cancers
Chen et al. Soluble programmed death ligand‐1‐induced immunosuppressive effects on chimeric antigen receptor‐natural killer cells targeting Glypican‐3 in hepatocellular carcinoma
KR20250128309A (ko) B7-h3을 표적으로 하는 항체 또는 항체 단편, 및 키메라 항원 수용체 면역 세포 요법 분야에서의 이의 응용